Existing evidence indicates that AHNAK overexpression activates the PI3K–Akt signaling pathway [51], which serves as a central metabolic regulator and may suppress glycolysis via downstream effectors, thereby reducing glycolytic metabolite production [52] and impairing tumor cell survival and invasiveness. This evidence concerns the gene AKT1 and neoplasm.